Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioOutsource Launches Flagship Reverse Signaling Apoptosis Bioassay

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Presents webinar on improving speed to market for Biosimilars.

BioOutsource Ltd. has announced the launch of the flagship Reverse Signaling Apoptosis Bioassay, adding to the extensive range of characterization services offered by the company. The assay is a critical method, required by the regulators for licensure of Humira and Remicade BioSimilars.

The Reverse Signaling Apoptosis bioassay replicates a critical component of TNF-Alpha biology whereby membrane bound TNF-Alpha acts as a receptor, mediating a negative feedback system following binding by the TNF2 receptor.

This results in cytokine suppression and the induction of apoptosis in TNF-Alpha producing cells, thereby dampening the elevated immune response.

BioOutsource CSO, Dr Daniel Galbraith commented; “We are delighted to be the first to bring the Reverse Signaling Apoptosis Assay to market. It completes our extensive range of characterization testing capabilities and ensures BioOutsource now support the full biological characterization of Humira and Remicade BioSimilars.”

In addition, BioOutsource also announced that Dr. Galbraith will shortly present a webinar on How Biological Characterization is improving speed to market for BioSimilars.

Dr. Galbraith commented “The webinar will present how the biological characterization of BioSimilar Monoclonal Antibodies plays a critical role in the development pathway for Biosimilars. I am looking forward to presenting our extensive experience in this area and engaging with thought leaders in the industry in the Q&A section”.

The webinar is being hosted in partnership with Business Review Webinars on 27th March 2014 at 3pm GMT.

BioOutsource has also announced that it will shortly be exhibiting at CHI’s Biotherapeutics Analytical Summit in Baltimore, USA on 24-28th March 2014, followed by Informa’s, BioProcessing International European Summit in Prague, Czech Republic on 2-3rd April 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioOutsource Ramps up Investment in R&D to Prepare for Biosimilars Boom
Already a leader in comparability of biosimilars, new R&D initiative aligns BioOutsources’ strategy with the next generation of biosimilars, to support client testing requirements and leverage rapid growth in biosimilars market.
Tuesday, November 04, 2014
BioOutsource Global Expansion
Plans to open a U.S. Lab Facility in Massachusetts in 2015.
Thursday, June 26, 2014
BioOutsource Expands ADC Characterization Capabilities
A global leader in ADC characterization, BioOutsource, partners with Glythera.
Wednesday, February 19, 2014
BioOutsource to Open Glasgow Biosimilar Centre of Excellence
The new facility will double the company’s capacity for the analysis of biosimilar monoclonal antibodies.
Wednesday, February 05, 2014
BioOutsource Opens New Facility in Cambridge, Massachusetts
First North American offices opened in response to surging demand for company’s BioAnalytical and Biosafety services.
Wednesday, May 01, 2013
Scientific News
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!